MUMBAI, India, November 4, 2011 /PRNewswire/ -- SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for

JAIPUR, India, September 20, 2011 /PRNewswire/ -- ~ To address the issue of High Infant & Child Mortality by focusing on: - Reducing Malnutrition

MUMBAI, India, May 16, 2011 /PRNewswire-FirstCall/ -- Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.

MUMBAI, India, March 3, 2011 /PRNewswire-FirstCall/ -- - This Press Release Supersedes and Replaces the Prior Release. Glenmark Generics Inc., USA (GGI), the United States subsidiary of Glenmark Generics Limited (GGL), announced they have been granted final approval for their Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (U.S.

MUMBAI, India, August 31, 2010 /PRNewswire-FirstCall/ -- - With This Announcement, Glenmark has Clearly Reaffirmed its Position Globally as the Leader in the TRP Space Glenmark Pharmaceuticals today announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'.